Group 1 - Citi Issuer Services, through Citibank, N.A., has been appointed as the Depositary Bank for POMDOCTOR LIMITED's American Depositary Receipt (ADR) program [1] - POMDOCTOR LIMITED is a Chinese online medical services platform [1] - The American Depositary Shares (ADS) of POM trade on the Nasdaq Stock Exchange under the ticker "POM" [1] Group 2 - Each six (6) ADSs represent one (1) Class A ordinary share of POM [1] - The initial public offering price is set at US$4.00 per ADS [1] - The total offering details are not specified in the provided content [1]

Core Viewpoint - POMDOCTOR LIMITED has successfully completed its initial public offering (IPO) with the underwriter exercising the option to purchase an additional 750,000 American Depositary Shares (ADSs) at a price of $4.00 per ADS, resulting in total gross proceeds of $23,000,016 before expenses [1]. Group 1: Offering Details - The IPO included an over-allotment option that was fully exercised, leading to the issuance of 750,000 additional ADSs [1]. - The total gross proceeds from the offering, including the over-allotment, amounted to $23 million [1]. - The ADSs began trading on the Nasdaq Global Market under the ticker symbol "POM" on October 8, 2025 [1]. Group 2: Company Overview - POMDOCTOR LIMITED is a leading online medical services platform in China, focusing on chronic disease management and pharmaceutical services [4]. - The company ranks sixth in China's Internet hospital market based on the number of contracted doctors as of 2022 [4]. - POMDOCTOR aims to enhance the efficiency and transparency of the healthcare value chain by connecting patients, doctors, and pharmaceutical products [4].

Group 1: Pepco Holdings, Inc. IPO - Pepco Holdings, Inc. is preparing for an initial public offering (IPO) on NASDAQ, planning to offer 5 million shares at a price of $4 each [1] - The IPO strategy mirrors that of POMDOCTOR LIMITED, which is also offering 5 million American Depositary Shares (ADSs) at the same price [1] Group 2: POMDOCTOR LIMITED IPO Details - POMDOCTOR LIMITED's IPO aims to raise approximately $20 million before expenses, with underwriters having the option to purchase an additional 750,000 ADSs within 45 days, potentially increasing total proceeds [2] - The ADSs will trade on the Nasdaq Global Market under the ticker "POM" starting October 8, 2025 [3] Group 3: POM Stock Performance - The current price of NYSE:POM is $14,500, reflecting a decrease of 1.03% or $150, with a trading range today between $14,350 and $14,650 [3] - Over the past year, POM has experienced significant price fluctuations, with a high of $21,500 and a low of $12,250, indicating volatility [3] - The trading volume for POM is 225,100 shares, suggesting active interest and liquidity in the market [3]

Core Insights - PomDoctor Ltd. raised approximately $20 million by pricing its shares at the lower end of the range, which is below the new Nasdaq minimum threshold of $25 million for foreign listings [2][7][8] Company Overview - PomDoctor is an internet-based healthcare provider focusing on chronic diseases, hosting a network of 212,800 doctors and nearly 700,000 patients, ranking sixth among China's internet hospitals [9] - The company reported a revenue of 343 million yuan ($48 million) for 2024, reflecting a 12.5% increase from 305 million yuan in 2023 [11] IPO Details - The IPO involved selling 5 million American depositary shares (ADS) at $4 per ADS, valuing the company at $472 million [5][7] - The pricing of the shares at the bottom of the range indicates a high price-to-sales (P/S) ratio of nearly 10, which is considered aggressive given the company's growth rate [7][12] Financial Position - PomDoctor reported losses of 37.4 million yuan last year and 36.9 million yuan in 2023, with total assets of 46.6 million yuan against total liabilities of 546 million yuan [13][14] - The company's financial position raises concerns about its ability to continue as a going concern, as noted by its auditor [14] Market Context - Compared to rivals like Ping An Health and JD Health, which have lower P/S multiples of 5.3 and 2.9 respectively, PomDoctor's valuation appears high [12] - The company lacks a strong financial backer, unlike its competitors, which may pose challenges for its business model [16]

Core Points - POMDOCTOR LIMITED has successfully closed its initial public offering (IPO) of 5,000,004 American Depositary Shares (ADSs) at a price of US$4.00 per ADS, raising approximately US$20.0 million in gross proceeds before expenses [1][2][3] Company Overview - POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in China, ranking sixth in the Internet hospital market based on contracted doctors in 2022 [5] - The company focuses on chronic disease management and pharmaceutical services, providing a one-stop platform that connects patients with doctors and pharmaceutical products [5] - POMDOCTOR aims to enhance the efficiency and transparency of the healthcare value chain, with a mission to provide effective prevention and treatment solutions for patients [5]